 |
eflornithine + sulindac |
|---|---|
| Trade Name | not avaiable |
| Orphan Indication | 1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole |
| EU Market Approval | EU |
| EU Designation Date | 2018-01-09 00:00:00 |
| Sponsor | Cancer Prevention Pharmaceutical, Inc. 1760 East River Road, Suite 250 Tucson, Arizona, 85718 |
